GeneDx Holdings Corp SEC Filings

Thomas Fuchs filed an initial Form 3 reporting his relationship to GeneDx Holdings Corp. (ticker: WGS) as a Director. The event date triggering the filing is 09/17/2025. The form states that no securities are beneficially owned by the reporting person. The filing is signed on behalf of Mr. Fuchs by Bridget Brown, Attorney-in-Fact dated 09/19/2025.

Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp. amended a Form 4 to correct a typographical error and to report the vesting and acquisition of restricted stock units. The amendment clarifies that on 09/16/2025 Mr. Feeley acquired 7,197 restricted stock units, each convertible into one share of Class A common stock for no consideration, increasing his beneficial ownership to 12,483 shares.

The filing notes the original Form 4 filed on 09/18/2025 incorrectly showed a disposition code where an acquisition code was intended; no other line items were changed. The amendment is signed by an attorney-in-fact on behalf of the reporting person.

GeneDx Holdings Corp. (WGS) Form 4 shows Chief Financial Officer Kevin Feeley reported transactions on 09/16/2025 related to the vesting and settlement of restricted stock units (RSUs). 7,197 RSUs were treated as vested and settled for no cash consideration, and the Reporting Person triggered a sell-to-cover transaction that sold 3,728 shares at a weighted average price of $121.4727 to satisfy tax withholding. After these transactions, Mr. Feeley directly beneficially owned 8,755 shares of Class A common stock.

In addition to direct holdings, the filing discloses contingent rights to receive 124,633 RSU shares and options to purchase 27,152 shares, which vest over time per their terms. The sale is described as non-discretionary and solely to cover withholding obligations.

Insider transactions reported for GeneDx Holdings Corp. (WGS) show Katherine Stueland received 18,750 restricted stock units (RSUs) on 09/16/2025 that convert to Class A common stock for no cash consideration upon settlement, and sold 10,501 shares of Class A common stock the same day at a weighted-average price of $121.4727 per share as part of a block trade. The sale was disclosed as a "sell to cover" transaction to satisfy tax withholding tied to the RSU vesting and was not discretionary. After these transactions the reporting person directly beneficially owned 14,578 shares of Class A common stock and, separately, beneficially owned RSUs representing up to 444,539 shares and options for 107,610 shares, subject to their vesting terms.

Amendment No. 9 to the Schedule 13D for GeneDx Holdings Corp. updates ownership and voting information for a group led by Eli Casdin and Keith Meister. The filing shows that Eli Casdin beneficially owns 3,599,671 shares (12.4%) and Keith A. Meister beneficially owns 3,630,826 shares (12.5%) of the Class A common stock, based on 28,726,248 shares outstanding as of July 24, 2025.

The filing attributes 3,007,164 shares (10.5%) to Casdin Partners Master Fund, L.P. and 3,058,629 shares (10.6%) to investment funds advised by Corvex Management LP. Certain reported holdings include shares issuable upon exercise of warrants and vested options (including 204,141 private placement warrants exercisable at $379.50 per share). The funds for the purchases listed were from the working capital of Casdin Partners Master Fund, L.P. Transactions in the past 60 days are reported in Exhibit B. The Amendment supplements earlier Schedule 13D filings and includes a joint filing agreement and transaction schedule as exhibits.